AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Somewhat Bullish +50

Is AbbVie (ABBV) Now Offering Value After Recent Share Price Weakness?

📉 AbbVie's stock price has recently weakened, declining 6.6% over the past week and 10.5% year-to-date while trading around US$205.20.

📊 Despite recent declines, the stock maintains a long-term track record with 5-year returns of 132.7% and a 44.5% gain over three years.

🧬 Investors are closely monitoring AbbVie due to ongoing attention on its product portfolio and competitive position within the large US pharmaceutical sector.

📊 Simply Wall St assigns AbbVie a value score of 3 out of 6, indicating it passes as undervalued on half of their six screening checks.

💰 A Discounted Cash Flow (DCF) model estimates an intrinsic value of US$366.91, suggesting the stock is approximately 44.1% below that DCF estimate.

📈 The DCF analysis specifically uses a Two-Stage Free Cash Flow to Equity approach with explicit analyst forecasts extending out to 2030.

💹 AbbVie currently trades at a P/E ratio of 86.68x, which is significantly higher than the peer average of 22.56x and industry average of 16.90x.

⚠️ Based on a proprietary Fair Ratio of 38.23x, the company's current valuation screens as overvalued compared to its earnings growth profile and risk factors.

📖 Simply Wall St suggests using "Narratives" to build custom fair value stories that align forecasts with specific views on revenue and earnings.

💡 One community narrative example estimates a fair value near US$253 using a 17.5x forward P/E multiplied by projected 2026 EPS of US$14.47.

🔍 Another investor perspective estimates a fair value around US$249 based on a 24.0x P/E applied to 2029 earnings forecasts.

⚠️ The article states that its analysis is general in nature, relies on historical data and analyst forecasts, and does not constitute financial advice.

🛑 Simply Wall St explicitly notes that their methodology may not factor in the latest price-sensitive announcements or specific qualitative material.

Bullish Signals
  • Although recent stock weakness has pushed the share price down, AbbVie still delivers a strong long-term performance with returns of 44.5% over the past three years and 132.7% over five years.
  • Based on a Discounted Cash Flow model, AbbVie trades at approximately 44.1% below its estimated intrinsic value of US$366.91, signaling significant upside potential.
  • The company generated robust free cash flow of around US$18.0b in the latest twelve months, with projections reaching US$31.5b by 2030.
  • Investors can utilize Simply Wall St's automated Narrative tools to track evolving forecasts for revenue, earnings, and fair value against a current market price of around US$205.
Risk Factors
  • AbbVie's share price has declined significantly, falling 6.6% over the past week, 8.7% over the past month, and 10.5% year to date, resulting in a current price of approximately US$205.
  • The stock's one-year return of 5.3% is lagging behind its peers, raising concerns about relative performance despite strong historical growth over longer periods.
  • On a P/E basis, AbbVie trades at a multiple of 86.68x, which sits well above Simply Wall St's Fair Ratio estimate of 38.23x and the industry average of 16.90x, suggesting significant overvaluation.
  • Simply Wall St's valuation model yields a score of only 3 out of 6, indicating that the company fails to screen as undervalued on the majority of key checks.
Full Analysis
According to Simply Wall St, AbbVie (ABBV) is currently trading at approximately US$205 per share, reflecting recent declines of 6.6% over the past week, 8.7% over the past month, and 10.5% year to date. Despite this recent weakness, the stock has generated returns of 5.3% over one year, 44.5% over three years, and 132.7% over five years. The analysis highlights that investor sentiment remains focused on AbbVie's product portfolio and its standing among large US pharmaceutical companies, as well as broader sector flows affecting healthcare valuations. A Discounted Cash Flow (DCF) model using a two-stage free cash flow to equity approach estimates AbbVie's intrinsic value at US$366.91 per share, based on the latest twelve-month free cash flow of approximately US$18.0 billion and projected figures reaching US$31.5 billion by 2030. This implies the stock is trading about 44.1% below its DCF estimate, signaling it may be undervalued according to this specific metric. The model uses explicit analyst estimates extending through 2030 before extrapolating further into the future to calculate current value. However, a Price-to-Earnings (P/E) analysis presents a contrasting view, showing AbbVie trading at a P/E ratio of 86.68x compared to a peer average of 22.56x and a biotech industry average of 16.90x. Simply Wall St calculates a fair P/E ratio of 38.23x for AbbVie based on its earnings growth, margins, and risk profile, which suggests the stock is overvalued relative to this metric since its current P/E significantly exceeds the fair estimate. The article concludes by suggesting investors can use "Narratives" on the Simply Wall St platform to reconcile these different valuation views, with community estimates of fair value ranging from US$249 to US$253 based on various forward earnings and multiplier assumptions. Simply Wall St assigns AbbVie an overall value score of 3 out of 6, indicating it screens as undervalued on half of the six evaluation checks. The platform notes that this analysis is general in nature, relies on historical data and analyst forecasts using an unbiased methodology, and does not constitute financial advice or a recommendation to buy or sell. The company has no position in any stocks mentioned and aims to provide long-term focused analysis driven by fundamental data without factoring in the latest price-sensitive announcements or qualitative material.